紅日藥業(300026.SZ):2020年度淨利預增30%-50%
格隆匯 1 月 27日丨紅日藥業(300026.SZ)披露2020年年度業績預吿,預計2020年年度歸屬於上市公司股東的淨利潤5.23億元—6.04億元,同比增長30%--50%。
本年度,公司以戰略為指引,以經營計劃為導向,整體上下同心,充分發揮自身優勢,積極投入到國內疫情防控工作中,利用國內快速復工復產的機會,拓展國外銷售渠道,加大醫療器械產品的出口業務,在逆境中求發展,營業收入和淨利潤較上年度均大幅增長。具體情況如下:
1、公司主力產品血必淨注射液銷售量較上年同期穩步增長。
2、中藥配方顆粒業務和原輔料業務經歷短暫的影響後,快速恢復到正常水平。
3、本年度公司醫療器械板塊國外訂單量較同期增長迅速,醫療器械配送業務也取得了較好的業績,收入和利潤增長較快。
4、截止2020年12月31日,公司本年度非經營性損益金額約為6100萬元-6300萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.